The EDGE

Defining and treating high-risk multiple myeloma

S Z Usmani, P Rodriguez-Otero, M Bhutani, M-V Mateos and J S Miguel

Leukemia 2015 29: 2119-2125; advance online publication, August 12, 2015; 10.1038/leu.2015.209

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

N M Kröger, J H Deeg, E Olavarria, D Niederwieser, A Bacigalupo, T Barbui, A Rambaldi, R Mesa, A Tefferi, M Griesshammer, V Gupta, C Harrison, H Alchalby, A M Vannucchi, F Cervantes, M Robin, M Ditschkowski, V Fauble, D McLornan, K Ballen, U R Popat, F Passamonti, D Rondelli and G Barosi

Leukemia 2015 29: 2126-2133; advance online publication, August 21, 2015; 10.1038/leu.2015.233

Original Articles

ACUTE MYELOID LEUKEMIA

Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms

R J Molenaar, S Thota, Y Nagata, B Patel, M Clemente, B Przychodzen, C Hirsh, A D Viny, N Hosano, F E Bleeker, M Meggendorfer, T Alpermann, Y Shiraishi, K Chiba, H Tanaka, C J F van Noorden, T Radivoyevitch, H E Carraway, H Makishima, S Miyano, M A Sekeres, S Ogawa, T Haferlach and J P Maciejewski

Leukemia 2015 29: 2134-2142; advance online publication, April 3, 2015; 10.1038/leu.2015.91

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia

A M Dorrance, P Neviani, G J Ferenchak, X Huang, D Nicolet, K S Maharry, H G Ozer, P Hoellarbauer, J Khalife, E B Hill, M Yadav, B N Bolon, R J Lee, L J Lee, C M Croce, R Garzon, M A Caligiuri, C D Bloomfield and G Marcucci

Leukemia 2015 29: 2143-2153; advance online publication, June 9, 2015; 10.1038/leu.2015.139

ACUTE LYMPHOBLASTIC LEUKEMIA

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

E Clappier, N Grardel, M Bakkus, J Rapion, B De Moerloose, P Kastner, A Caye, J Vivent, V Costa, A Ferster, P Lutz, F Mazingue, F Millot, D Plantaz, G Plat, E Plouvier, M Poirée, N Sirvent, A Uyttebroeck, K Yakouben, S Girard, N Dastugue, S Suciu, Y Benoit, Y Bertrand and H Cavé on behalf of the EORTC-CLG

Leukemia 2015 29: 2154-2161; advance online publication, June 8, 2015; 10.1038/leu.2015.134

LYMPHOMA

Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism

V Atsaves, R Zhang, D Ruder, Y Pan, V Leventaki, G Z Rassidakis and F X Claret

Leukemia 2015 29: 2162-2172; advance online publication, May 19, 2015; 10.1038/leu.2015.127

MULTIPLE MYELOMA, GAMMOPATHIES

Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo OPEN

E Morelli, E Leone, M E Gallo Cantafio, M T Di Martino, N Amodio, L Biamonte, A Gullà, U Foresta, M R Pitari, C Botta, M Rossi, A Neri, N C Munshi, K C Anderson, P Tagliaferri and P Tassone

Leukemia 2015 29: 2173-2183; advance online publication, May 19, 2015; 10.1038/leu.2015.124

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib OPEN

S Jagannathan, M A Y Abdel-Malek, E Malek, N Vad, T Latif, K C Anderson and J J Driscoll

Leukemia 2015 29: 2184-2191; advance online publication, June 25, 2015; 10.1038/leu.2015.157

CHRONIC MYLEPROLIFERATIVE NEOPLASMS

Protein kinase Cε inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients

E Masselli, C Carubbi, G Gobbi, P Mirandola, D Galli, S Martini, S Bonomini, M Crugnola, L Craviotto, F Aversa and M Vitale

Leukemia 2015 29: 2192-2201; advance online publication, June 19, 2015; 10.1038/leu.2015.150

STEM CELL BIOLOGY

Protracted dormancy of pre-leukemic stem cells OPEN

A M Ford, M B Mansur, C L Furness, F W van Delft, J Okamura, T Suzuki, H Kobayashi, Y Kaneko and M Greaves

Leukemia 2015 29: 2202-2207; advance online publication, May 28, 2015; 10.1038/leu.2015.132

Control of AC133/CD133 and impact on human hematopoietic progenitor cells through nucleolin

S Bhatia, S Reister, C Mahotka, R Meisel, A Borkhardt and E Grinstein

Leukemia 2015 29: 2208-2220; advance online publication, June 19, 2015; 10.1038/leu.2015.146

MOLECULAR TARGETS FOR THERAPY

Disruption of the 5S RNP–Mdm2 interaction significantly improves the erythroid defect in a mouse model for Diamond-Blackfan anemia

P Jaako, S Debnath, K Olsson, Y Zhang, J Flygare, M S Lindström, D Bryder and S Karlsson

Leukemia 2015 29: 2221-2229; advance online publication, May 19, 2015; 10.1038/leu.2015.128

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia

G Wedeh, S Cerny-Reiterer, G Eisenwort, H Herrmann, K Blatt, E Hadzijusufovic, I Sadovnik, L Müllauer, J Schwaab, T Hoffmann, J E Bradner, D Radia, W R Sperr, G Hoermann, A Reiter, H-P Horny, J Zuber, M Arock and P Valent

Leukemia 2015 29: 2230-2237; advance online publication, June 9, 2015; 10.1038/leu.2015.138

IMMUNOTHERAPY

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

Q Zhao, M Ahmed, D V Tassev, A Hasan, T-Y Kuo, H-F Guo, R J O'Reilly and N-K V Cheung

Leukemia 2015 29: 2238-2247; advance online publication, May 19, 2015; 10.1038/leu.2015.125

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE

BAALC potentiates oncogenic ERK pathway through interactions with MEKK1 and KLF4

K Morita, Y Masamoto, K Kataoka, J Koya, Y Kagoya, H Yashiroda, T Sato, S Murata and M Kurokawa

Leukemia 2015 29: 2248-2256; advance online publication, June 8, 2015; 10.1038/leu.2015.137

Letters To The Editor

The stability of epigenetic factor ASXL1 is regulated through ubiquitination and USP7-mediated deubiquitination

D Inoue, K Nishimura, H Kozuka-Hata, M Oyama and T Kitamura

Leukemia 2015 29: 2257-2260; advance online publication, April 3, 2015; 10.1038/leu.2015.90

Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival

U Creutzig, M N Dworzak, M Zimmermann, J-P Bourquin, B Gruhn, G Fleischhack, N Graf, T Klingebiel, B Kremens, T Lehrnbecher, C von Neuhoff, A v Stackelberg, J Starý and D Reinhardt

Leukemia 2015 29: 2260-2263; advance online publication, April 14, 2015; 10.1038/leu.2015.94

Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

W Wang, J E Cortes, P lin, J D Khoury, D Ai, Z Tang, G Tang, J L Jorgensen, L J Medeiros and S Hu

Leukemia 2015 29: 2263-2266; advance online publication, April 14, 2015; 10.1038/leu.2015.96

Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy

N Lachmann, K Czarnecki, S Brennig, R Phaltane, M Heise, N Heinz, H Kempf, D Dilloo, V Kaever, A Schambach, M Heuser and T Moritz

Leukemia 2015 29: 2266-2269; advance online publication, April 29, 2015; 10.1038/leu.2015.108

Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs

J Chapman, A J Gentles, V Sujoy, F Vega, C I Dumur, T L Blevins, L Bernal-Mizrachi, M Mosunjac, A Pimentel, D Zhu and I S Lossos

Leukemia 2015 29: 2270-2273; advance online publication, April 24, 2015; 10.1038/leu.2015.109

Corrigendum

Ectopic expression of c-myc fails to overcome downregulation of telomerase activity induced by herbimycin A, but ectopic hTERT expression overcomes it

M Akiyama, O Yamada, S Akita, M Urashima, J Horiguchi-Yamada, T Ohno, H Mizoguchi, Y Eto and H Yamada

Leukemia 2015 29: 2274; 10.1038/leu.2015.266